Form SC14D9C - Written communication relating to third party tender offer
August 07 2024 - 4:10PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14D-9
(Rule 14d-101)
SOLICITATION/RECOMMENDATION STATEMENT
UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934
G1 THERAPEUTICS, INC.
(Name of Subject Company)
G1
THERAPEUTICS, INC.
(Name of Persons Filing Statement)
COMMON STOCK PAR VALUE $0.0001 PER SHARE
(Title of Class of Securities)
3621LQ109
(CUSIP Number
of Class of Securities)
Monica Roberts Thomas, Esq.
Chief Legal and People Officer
700 Park Offices Drive, Suite 200
Research Triangle Park, NC 27709
With copies to:
|
|
|
Matthew J. Gardella, Esq.
Jason S. McCaffrey, Esq.
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
One Financial Center
Boston, MA 02111 (617) 542-6000 |
|
Sarah Young, Esq.
Ropes and Gray LLP
Prudential Tower 800
Boylston Street Boston, MA 02199
(617) 951-7000 |
(Name, address, and telephone numbers of person authorized to receive notices and communications on behalf of
the persons filing statement)
☒ |
Check the box if the filing relates solely to preliminary communications made before the commencement of a
tender offer. |
The information set forth under Items 1.01, 5.02 and 9.01 of the Current Report on Form 8-K filed by G1 Therapeutics,
Inc. on August 7, 2024 (including all exhibits attached hereto) is incorporated herein by reference.
G1 Therapeutics (NASDAQ:GTHX)
Historical Stock Chart
From Sep 2024 to Oct 2024
G1 Therapeutics (NASDAQ:GTHX)
Historical Stock Chart
From Oct 2023 to Oct 2024